CD4 and myeloid sarcoma: This has been shown, for example, for regulatory T cells (Treg), which have reduced suppressive potential in MS.30 Therefore, although MSC treatment of MS can increase the proportion of CD4+CD25+ T cells,31 the regulatory capacity of these cells may be reduced.